Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
Research and development	$ 27,521,400	$ 7,603,081
General and administrative	4,970,057	2,818,392
Total operating expenses	32,491,457	10,421,473
Loss from operations	(32,491,457)	(10,421,473)
Interest and amortization of debt discount (expense)	7,311	(218,903)
Net loss	$ (32,484,146)	$ (10,640,376)
Net loss per common share, basic and diluted	$ (0.88)	$ (0.32)
Weighted average common shares outstanding, basic and diluted	37,061,356	33,052,468